We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+7.83%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$658M
AUM Growth
-$44.8M
Cap. Flow
-$69.2M
Cap. Flow %
-10.5%
Top 10 Hldgs %
35.22%
Holding
143
New
39
Increased
27
Reduced
22
Closed
45

Top Buys

Rank Stock Value
1
SNN icon
Smith & Nephew
SNN
+$10.3M
2
STAA icon
STAAR Surgical
STAA
+$7.04M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$6.66M
4
ZBH icon
Zimmer Biomet
ZBH
+$6.03M
5
AVTR icon
Avantor
AVTR
+$4.45M

Top Sells

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$10.4M
2
AXGN icon
Axogen
AXGN
+$6.9M
3
CELG
Celgene Corp
CELG
+$4.72M
4
AXSM icon
Axsome Therapeutics
AXSM
+$4.13M
5
GMED icon
Globus Medical
GMED
+$3.47M

Sector Composition

Rank Sector Weight
1 Healthcare 44.69%
2 Industrials 1.24%
3 Consumer Staples 0.68%
4 Materials 0.13%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENT
51
CALL
DELISTED
Intersect ENT, Inc
XENT
$4.55M 0.69%
200,000
+100,000
+100% +$2.7M
GNLN icon
52
Greenlane Holdings
GNLN
$1.23M
– –
0
– –
CTLT
53
DELISTED
CATALENT, INC.
CTLT
$4.34M 0.66%
+80,000
New +$3.66M
SPPI
54
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$4.3M 0.65%
+500,000
New +$4.47M
OMCL icon
55
PUT
Omnicell
OMCL
$1.7B
$4.3M 0.65%
+50,000
New +$4.06M
CNMD icon
56
CONMED
CNMD
$1.48B
$4.28M 0.65%
50,000
+10,000
+25% +$822K
AXGN icon
57
PUT
Axogen
AXGN
$2.59B
$3.96M 0.6%
+200,000
New +$4.28M
ITCI
58
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.89M 0.59%
+300,000
New +$3.85M
AVNS
59
DELISTED
Avanos Medical
AVNS
$3.71M 0.56%
85,000
-2,500
-3% -$107K
AZTA icon
60
Azenta
AZTA
$1.54B
$3.68M 0.56%
+95,000
New +$3.41M
WMGI
61
DELISTED
Wright Medical Group Inc
WMGI
$3.65M 0.55%
122,500
-17,500
-13% -$534K
INGN icon
62
CALL
Inogen
INGN
$160M
$3.34M 0.51%
+50,000
New +$3.81M
VAPO
63
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$3.22M 0.49%
17,500
-3,522
-17% -$521K
ARAY icon
64
CALL
Accuray
ARAY
$34.9M
$3.1M 0.47%
800,000
-200,000
-20% -$808K
BAX icon
65
Baxter International
BAX
$14.4B
$3.07M 0.47%
37,500
-32,500
-46% -$2.52M
TGTX icon
66
TG Therapeutics
TGTX
$7.52B
$3.07M 0.47%
354,719
+290,000
+448% +$2.19M
UTHR icon
67
United Therapeutics
UTHR
$22.7B
$3.04M 0.46%
+39,000
New +$3.65M
LAB icon
68
Standard BioTools
LAB
$310M
$2.96M 0.45%
240,000
-180,000
-43% -$2.29M
BDSI
69
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.91M 0.44%
625,235
-75,243
-11% -$350K
LIVN icon
70
PUT
LivaNova
LIVN
$4.21B
$2.88M 0.44%
+40,000
New +$2.93M
OTIC
71
DELISTED
Otonomy, Inc.
OTIC
$2.73M 0.41%
993,463
– –
CNCE
72
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$2.7M 0.41%
224,900
– –
APYX icon
73
Apyx Medical
APYX
$146M
$2.67M 0.41%
+397,272
New +$2.16M
AXNX
74
DELISTED
Axonics, Inc. Common Stock
AXNX
$2.66M 0.4%
+65,000
New +$1.83M
SILK
75
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$2.42M 0.37%
+50,000
New +$2.13M
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q2 2019 Portfolio in Review

As of Q2 2019, Pura Vida Investments held 143 positions worth $658M, down 6.4% from $703M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Pura Vida Investments withdrew a net $69.2M in Q2 2019, closing 45 positions and reducing 22 holdings. Its most notable exit was Dentsply Sirona, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 36% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Smith & Nephew worth $10.9M.

  • Pura Vida Investments's largest Q2 2019 buy was Smith & Nephew: 250,000 shares worth $10.9M.
  • Pura Vida Investments added most to STAAR Surgical in Q2 2019, an estimated $7.04M increase.
  • Pura Vida Investments's biggest Q2 2019 reduction was Axsome Therapeutics, cutting an estimated $4.13M.
  • Pura Vida Investments fully exited Dentsply Sirona in Q2 2019, selling an estimated $10.4M.
  • Pura Vida Investments's ten largest holdings make up 35% of its $658M portfolio in Q2 2019.
  • Pura Vida Investments opened 39 new positions and closed 45 in Q2 2019.
  • Pura Vida Investments's portfolio value fell 6.4% quarter-over-quarter to $658M.

Based on Pura Vida Investments's 13F filing for Q2 2019, filed 14 Aug 2019.